AS

Alek Safarian

CEO at ALSA Ventures

London, England

Invests in

Stages:

Sectors:

Pharmaceuticals

Locations:

Min Investment:
$100,000.00
Max Investment:
$5,000,000.00
Target Investment:
$1,500,000.00

Skills

Education

MBA
University of Sydney
(1993 - 1995)
B.Pharm.
University of Sydney
(1984 - 1986)
St. Benedict's Grammar School
(1978 - 1982)

Work Experience

2018

CEO
2018

1996 - 2017

Member of the Board of Directors
1996 - 2017
CEO
1996 - 2017
Executive responsibility for day to day operations of the company, setting strategy together with management team and board, executing on the company's growth strategy.

Marion Merrell Dow (now Sanofi-Aventis)

1990 - 1995

Head, Scientific Affairs, Asia-Pacific
1990 - 1995
Based in Sydney, headed the regulatory affairs function and post-marketing research in 11 countries in the Asia-Pacific including Australia, China, Korea, Taiwan, and Singapore. Left MMD just before merger with Hoechst Roussel to found Novotech.

Ciba-Geigy (now Novartis)

1988 - 1990

Regulatory Affairs Associate
1988 - 1990